[
    [
        {
            "time": "2019-07-09",
            "original_text": "研发投入近4000万，恒瑞子公司抗癌药首仿上市！同品种天晴/齐鲁在审！",
            "features": {
                "keywords": [
                    "恒瑞",
                    "抗癌药",
                    "首仿",
                    "研发投入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "研发投入近4000万，恒瑞子公司抗癌药首仿上市！同品种天晴/齐鲁在审！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "3年亏损逾9亿，百奥泰选用第5套标准闯关科创板 亏损",
            "features": {
                "keywords": [
                    "百奥泰",
                    "科创板",
                    "亏损"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3年亏损逾9亿，百奥泰选用第5套标准闯关科创板 亏损",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "恒瑞重磅首仿药获批 国内药企注册进度几何？",
            "features": {
                "keywords": [
                    "恒瑞",
                    "首仿药",
                    "获批"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞重磅首仿药获批 国内药企注册进度几何？",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "恒瑞医药（600276.SH）：醋酸阿比特龙片获药品注册批件",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "醋酸阿比特龙片",
                    "注册批件"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药（600276.SH）：醋酸阿比特龙片获药品注册批件",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "谁在接盘新城? \"黑天鹅\"后新城发展与新城悦明显放量",
            "features": {
                "keywords": [
                    "新城",
                    "黑天鹅",
                    "放量"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "谁在接盘新城? \"黑天鹅\"后新城发展与新城悦明显放量",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "恒瑞医药：仿创结合持续推进 买入评级",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "仿创结合",
                    "买入评级"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：仿创结合持续推进 买入评级",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "最新公告透露利好 15只个股有望爆发（07.09）",
            "features": {
                "keywords": [
                    "公告",
                    "利好",
                    "个股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "最新公告透露利好 15只个股有望爆发（07.09）",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "恒瑞卡瑞利珠单抗二线治疗晚期食管鳞癌达主要终点",
            "features": {
                "keywords": [
                    "恒瑞",
                    "卡瑞利珠单抗",
                    "食管鳞癌",
                    "主要终点"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞卡瑞利珠单抗二线治疗晚期食管鳞癌达主要终点",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-09",
            "original_text": "格力拟斥资2亿元入股新疆众和成第三大股东，第一大股东特变电工持股升至30.85%；多家券商披露6月业绩；平安再度耗资超5亿回购",
            "features": {
                "keywords": [
                    "格力",
                    "新疆众和",
                    "特变电工",
                    "券商",
                    "平安",
                    "回购"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "家电",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格力拟斥资2亿元入股新疆众和成第三大股东，第一大股东特变电工持股升至30.85%；多家券商披露6月业绩；平安再度耗资超5亿回购",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]